Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Velcade in Waldenstrom's Macroglobulinemia

NCT00142129 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT00142129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00142129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Velcade in Waldenstrom's Macroglobulinemia
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2003
Completion date
June 30, 2007
Enrollment
27
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoplasmacytic lymphoma, waldenstrom's macroglobulinemia